<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238225</url>
  </required_header>
  <id_info>
    <org_study_id>I 33204</org_study_id>
    <secondary_id>RPCI-I-33204</secondary_id>
    <nct_id>NCT00238225</nct_id>
  </id_info>
  <brief_title>Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors</brief_title>
  <official_title>A Phase I Study of Oral Calcitriol in Combination With Ketoconazole in Refractory Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Calcitriol may cause solid tumor cells to look more like normal cells, and to grow&#xD;
      and spread more slowly. Ketoconazole and dexamethasone may help calcitriol work better by&#xD;
      making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole&#xD;
      and dexamethasone may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when&#xD;
      given together with ketoconazole and dexamethasone in treating patients with metastatic or&#xD;
      unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of calcitriol when administered with ketoconazole&#xD;
           and dexamethasone in patients with metastatic or unresectable solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tolerability and toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of calcitriol and dexamethasone with or without&#xD;
           ketoconazole in these patients.&#xD;
&#xD;
        -  Determine the pharmacodynamics of this regimen, in terms of CYP24 expression and&#xD;
           activity and vitamin D receptor expression in peripheral blood mononuclear cells, in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of calcitriol.&#xD;
&#xD;
      Patients receive oral dexamethasone twice daily beginning on day 0 and oral ketoconazole 3&#xD;
      times daily beginning on day 4. Patients also receive oral calcitriol once daily on days 1-3&#xD;
      of each week. Treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of calcitriol</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of calcitriol and dexamethasone with or without ketoconazole</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcitriol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Standard curative or reliable palliative therapy is no longer effective OR does not&#xD;
             exist&#xD;
&#xD;
          -  Brain metastases allowed provided they have been treated with surgery or radiotherapy&#xD;
             AND are stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No unstable or uncompensated hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  No unstable or uncompensated renal disease&#xD;
&#xD;
          -  No history of kidney, urethral, or bladder stones within the past 5 years&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 30%&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No significant arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No unstable or uncompensated cardiac disease&#xD;
&#xD;
          -  No other significant heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No unstable or uncompensated respiratory disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known severe hypersensitivity to ketoconazole or calcitriol or any of the&#xD;
             excipients of these products&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to the study drugs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to, during, and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Able to receive oral medication&#xD;
&#xD;
          -  No sperm donation during and for ≥ 3 months after completion of study treatment&#xD;
&#xD;
          -  No evidence of significant clinical disorder or laboratory finding that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No other severe or uncontrolled systemic disease&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors, including filgrastim (G-CSF) or&#xD;
             sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
               -  Any number of prior chemotherapy regimens allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic glucocorticoid therapy &gt; physiologic replacement doses&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Any number of prior radiotherapy regimens allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
          -  Concurrent surgery allowed provided ≥ 7 days has passed since the last dose of&#xD;
             ketoconazole (ketoconazole may be restarted after adequate wound healing)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior anticancer therapy&#xD;
&#xD;
               -  Alopecia allowed&#xD;
&#xD;
          -  More than 30 days since prior nonapproved or investigational agents&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent thiazides&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent digoxin or calcium supplementation&#xD;
&#xD;
          -  No concurrent proton pump inhibitor or H2 blockers&#xD;
&#xD;
          -  No concurrent medications that would alter the levels of ketoconazole and/or&#xD;
             calcitriol, including the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates (e.g., phenobarbital)&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent drugs that would be significantly impaired in a clinically important way&#xD;
             by ketoconazole&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald L. Trump, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

